

## HISTORICALLY ACCEPTED USE

### Tertiary and Quaternary Committee

#### Executive Summary

<p><b>Date:</b> March 2019</p> <p><b>Medicine (INN):</b> Ifosfamide injection</p> <p><b>Medicine (ATC):</b> L01AA06</p> <p><b>Indication (ICD10 code):</b> germ cell tumours, soft tissue sarcomas, salvage therapy in lymphomas pre-autologous stem cell transplant.</p> <p><b>Patient population:</b> adults and children</p> <p><b>Prevalence of condition:</b> testicular cancer 170 patients per year (0.63/100 000); ovarian cancer 493 patients per year (2.12/100 000); incidence of soft tissue sarcomas in South Africa is unknown.</p> <p><b>Level of Care:</b> Tertiary and Quaternary</p> <p><b>Prescriber Level:</b> Oncologist</p> <p><b>Current standard of Care:</b> Ifosfamide in combination with doxorubicin.</p> <p><b>Efficacy estimates:</b> In combination with mesna in previously failed sarcomas, 3% responded completely (95% CI 1% to 8%) and 21% had a complete or partial response (95% CI 14% to 29%).<sup>1</sup></p>
--

#### Historically accepted use Criteria

Criteria		Comment	
1	The medicine is included in the WHO Model Essential Medicines List, either as a core or complementary item, for the indication requested.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
2	The medicine is currently registered by SAHPRA for the indication.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
3	There is evidence of long-established (prior to 1996*) safe and effective use of the medicine for the recognised indication in the public health sector.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	
4	There are no new safety or efficacy concerns.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	
5	The budget impact is not expected to be sufficiently large that a <i>de novo</i> review is justified.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	
6	There is equitable access across the country, and is limited only by the availability of adequately trained staff and availability of equipment.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	

\* The Essential Drugs Programme (EDP) of South Africa was established in terms of the National Drug Policy (NDP) which was implemented in 1996

## Recommendation

It is recommended that ifosfamide be included as an Essential Medicine in the management of germ cell tumours, soft tissue sarcomas, salvage therapy in lymphomas pre-autologous stem cell transplant.

---

<sup>1</sup> Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. *Journal of Clinical Oncology*. 1989, 7 (1): 126-131.